Klaudija Batinic, Clemens Höbaus, Milan Grujicic, Angelika Steffan, Finka Jelic, David Lorant, Thomas Hörtenhuber, Florian Hoellerl, Johanna-Maria Brix, Guntram Schernthaner, Renate Koppensteiner, Gerit-Holger Schernthaner
OBJECTIVE: YKL-40 is secreted by macrophages in atherosclerotic lesions and involved in plaque rupture. YKL-40 is elevated in coronary artery disease, and predicts cardiovascular mortality. Experimental in vivo and in vitro data suggest a role of YKL-40 in tissue remodeling. A disease modulating potency of YKL-40 was not investigated in peripheral arterial disease (PAD). METHODS: We measured YKL-40 in 460 subjects: 316 PAD: 71 normal glucose metabolism (PAD-NGM), 90 pre-diabetes (PAD-PREDM) and 155 diabetes (PAD-DM); 20 diabetes with atherosclerosis but without PAD (AS-DM); 85 diabetes without macro-vascular complications (DM) and 39 healthy controls (CO)...
June 2012: Atherosclerosis